PHARMACEUTICAL COMPOSITION

• US 20100151014A1
• Filed: 12/16/2008
• Published: 06/17/2010
• Est. Priority Date: 12/16/2008
• Status: Abandoned Application

• Current Assignee: Alpharma Pharmaceuticals LLC (Pfizer Inc.)
• Original Assignee: Alpharma Pharmaceuticals LLC (Pfizer Inc.)
• Inventors: Johnson, Frank, Tang, Lijuan, Stauffer, Joseph, Boehm, Garth, Liang, Alfred, Matthews, Frank
• Application Number:
  US12/336,418
• Publication Number:
  US 20100151014A1
• Time in Patent Office: Days
• US Class Current: 424/457
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids

Abstract

Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated.

Claims

1. A method of creating a condition in a host that is responsive to an agonist, the method comprising administering a multi-layer pharmaceutical composition comprising an agonist and an antagonist thereof that are not in direct contact with one another in the intact form of the composition, wherein administration of the intact form of the composition to the host effectively treats the condition in a manner more efficacious than placebo when measure using the Brief Pain Inventory.

2. The method of claim 1 wherein the host is treated for tip to twelve, weeks.

3. A method of treating a condition in a host that is responsive to an agonist, the method comprising administering a multi-layer pharmaceutical composition comprising an agonist and an antagonist thereof that, are not in direct contact with one another in the intact form of the composition, wherein administration of the intact form of the composition to the host, effectively treats the condition in a manner more efficacious than placebo when measured using the WOMAC Osteoarthritis Index.

4. The method of claim 4 wherein the host is treated for tip to twelve weeks.